Drug Safety

Advice on Multi-Drug Failures in RA

Save

Jack Cush, MD

Sep 25, 2023

What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics? In such cases you have to either reconsider the diagnosis (especially if seronegative) or reach into your bag of tricks.

As many of us struggle with multi-drug

Read Article

TNR: Decisions in Methotrexate This Tuesday Night Rheumatology panel discussion on "MTX Decisions" features Drs. Michael Weinblatt, Grace Wright, Richard Conway and Joel Kremer. The Panel discussed folate & MTX dosing, side effect management, and more. https://t.co/Q44VYhgAzJ https://t.co/4ndTBvS1mc

RheumNow @Dr. John Cush( View Tweet )

Sep 22, 2023

Join us for our final webinar this month, DMARD Choices & Changes. The panel will discuss rheumatologists' choices in choosing 2nd line & 3rd line DMARD therapy, when or if to wean/de-escalate DMARDs and how to proceed with restarting therapy when needed. https://t.co/cRb1E79QLB https://t.co/JbRp3P1TO8

RheumNow @Dr. John Cush( View Tweet )

Sep 22, 2023

Update on Anti-Drug Antibodies and Therapeutic Drug Monitoring

Save

Blair Solow, MD, MSc

Sep 21, 2023

We use biologic agents on a daily basis in the treatment of rheumatoid arthritis. Despite having an expanding array of options, our profession is keen on gaining a deeper understanding of why certain drugs fail and being able to predict the most appropriate next steps in treatment.

Read Article

#RA QD Clinic: Enough with the Steroids Features Dr. Jack Cush RA patient not doing well - Should you use Steroids? How much, how long & guideline guidance RA QD Clinics are video vignettes with lessons from the clinic. https://t.co/dOpTwhkuIP https://t.co/dJmjHyKSS3

RheumNow @Dr. John Cush( View Tweet )

Sep 21, 2023

TNR: Decisions in Methotrexate

Save

Jack Cush, MD

Sep 20, 2023

This Tuesday Night Rheumatology panel discussion on "Methotrexate Decisions" features Drs. Michael Weinblatt, Grace Wright, Richard Conway and Joel Kremer. The Panel discussed folate & MTX dosing, side effect management, MTX & lung disease and optimal monitoring, with many audience

Read Article

Tomorrow! Join us for Decisions in MTX at 7pm ET. https://t.co/SRjj64QPeW https://t.co/JSAPjDxKYn

RheumNow @Dr. John Cush( View Tweet )

Sep 18, 2023

QD Clinic: RA and medication induced ulcers Dr. Bella Mehta, a rheumatologist from New York, presents this QD clinic on medication induced ulcers as part of RheumNow's Hard Decisions in #RA campaign. https://t.co/AVjUYltVvK https://t.co/mVI1oQob0Z

RheumNow @Dr. John Cush( View Tweet )

Sep 18, 2023

Watch Drs. Janet Pope and Alvin Wells debate Triple DMARD Therapy Drs. Janet Pope and Alvin Wells debate triple DMARD therapy. These and more debates and perspectives on Hard Decisions in #RA now available. https://t.co/f59Wh3lnHX @janetbirdope @alvinwellsmd https://t.co/H2F4wOElSw

RheumNow @Dr. John Cush( View Tweet )

Sep 16, 2023

Prospective cohort study of 41 Stills Dz pts w/ ILD - 85% had 1+MAS & 41% with adverse reactions to a biologic. 93% were alive w/ median F/U 3 years, but 37% progressed to chronic lung dz (O2, or vent) & 84% were HLA-DRB1*15 https://t.co/fo44fgKh8m https://t.co/xa9g4Slr1H

RheumNow @Dr. John Cush( View Tweet )

Sep 14, 2023

TNR: Early RA - Referrals and Treatment

Save

Jack Cush, MD

Sep 13, 2023

This Tuesday Night Rheumatology was an hour long panel discussion featuring Drs. Jack Cush, Vivian Bykerk, Glen Hazelwood and Martin J. Bergman.

The Panel discussed Rheumatologists views on Early RA referral and intake, initial treatment preferences and views on diagnosing and treating pre-

Read Article

Hydroxychloroquine Adherence Lowers Cardiovascular Risks

Save

Jack Cush, MD

Sep 11, 2023

Daily hydroxychloroquine (HCQ) is better than an apple a day; as a new study shows that adherence to the antimalarial agent significantly lowers future risk of cardiovascular events in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.

Read Article

Full read review of Colchicine drug interactions - primarily inhibitors of CYP3A4 (includes statins, amiodarone, cyclosporine, voriconazole). Signs of colchicine toxicity include diarrhea, myalgia, weakness, myoglobinuria, BM suppression/cytopenias. https://t.co/qddOnCJc5x https://t.co/2yGlr4nXmF

RheumNow @Dr. John Cush( View Tweet )

Sep 09, 2023

SAVE THE DATE! RheumNow Live will now be taking place in January! Who is joining us? https://t.co/EdrLp87Z81

RheumNow @Dr. John Cush( View Tweet )

Sep 09, 2023

QD Clinic - MTX Pearls Active RA needs to change meds but cannot handle higher doses of MTX. #RA QD Clinics are video vignettes with lessons from the clinic. RA QD Clinics and the "Hard Decisions in RA" September Campaign is sponsored by BMS. https://t.co/ExwgtWjeNj https://t.co/0JO84tMV0O

RheumNow @Dr. John Cush( View Tweet )

Sep 08, 2023

Oral Surveillance Changes in Advanced Therapy Use in #RA The safety of tofacitinib and TNF inhibitors was studied in high risk RA patients in the ORAL Surveillance study. Read more.... https://t.co/2ZyB0xow6B https://t.co/mB5R0HfaWq

RheumNow @Dr. John Cush( View Tweet )

Sep 08, 2023

RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)

Save

Jack Cush, MD

Sep 08, 2023

This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".

Read Article

Miss this week's TNR on Oral Surveillance Revisited? Watch the playback here. Join an hour long panel discussion featuring Drs. Janet Pope, Jeff Curtis, Jon Giles and Roy Fleischmann. TNR is sponsored by BMS. #RA https://t.co/Q6zptUxDaW https://t.co/HPuQXWZSBr

RheumNow @Dr. John Cush( View Tweet )

Sep 07, 2023

#RA QD Clinic - RA & Vaccination An RA patient needs vaccination - how do you handle the meds? RA QD Clinics are video vignettes with lessons from the clinic. RA QD Clinics and the "Hard Decisions in RA" September Campaign is sponsored by BMS. https://t.co/ktNZIpInMS https://t.co/fsobHjTq1v

RheumNow @Dr. John Cush( View Tweet )

Sep 06, 2023

Anifrolumab targets type I IFN pathway. In #SLE Trials, pts on ANIF had as much as 8-fold higher rate of Herpes zoster. HZ incidence is 6.9 vs 1.5/100 PYs on ANIF vs PBO. Other drugs may affect IFN - sifalimumab litifilimab, daxdilimab, deucravacitinib https://t.co/V6BceVjRDc https://t.co/lcjbjS9uZt

RheumNow @Dr. John Cush( View Tweet )

Sep 04, 2023

Hard Decisions in RA (9.1.2023)

Save

Jack Cush, MD

Sep 01, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article

SAVE THE DATE! RheumNow Live will now be taking place in January! Will you be there? https://t.co/WCfBzthXvl

RheumNow @Dr. John Cush( View Tweet )

Aug 31, 2023

Posthoc analysis 2 phase III RCTs of ABAtacept x 2 yrs in 409 poly JIA pts; ABA monoRx vs ABA+MTX Rx pts were compared & there were NO between group differences in efficacy (JIA-ACR & JADAS27-CRP), bio-naive vs bio-experience responses, safety & PK studies https://t.co/lBJrPzm5S1 https://t.co/RM542Hl8Fu

RheumNow @Dr. John Cush( View Tweet )

Aug 30, 2023

SGLT2 Inhibitors as Gout Treatment

Save

MedPage Today

Aug 30, 2023

Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said.

Read Article

Retrospective study of 41 pts w/ refractory inflammatory myositis treated with tofacitinib; (23 DM, 12 CADM & 6 PM). In ALL pts - no improvement in strength observed, but Skin did improve! 54% discontinued TOFA for lack of benefit or death. https://t.co/NPgdeOuw8C https://t.co/jBSqhSk29Y

RheumNow @Dr. John Cush( View Tweet )

Aug 29, 2023

Recent Blogs

Comorbidities in RA: Focus on Difficult-to-Treat Disease

Save

Elena Nikiphorou, MD, PhD

Sep 26, 2023

Patients with RA have on average two additional other clinical conditions and research shows that these accumulate over time and with longer disease duration. The presence of comorbidities naturally complicates treatment choice, patient adherence to medication and patient outcomes, increasing also the risk of making RA ‘difficult-to-treat’. Read Post

Infections Rheums Should Worry About

Save

Cassandra Calabrese, DO

Sep 20, 2023

With the increasing development and use of new biologics and oral targeted therapies to treat RA and other immune mediated inflammatory diseases, an awareness of infection risk and prevention has become of increasing interest as well. While our patients may be susceptible to many different types of infections depending on immunosuppressive regimen, age and co-morbidities, I’ll highlight a few of the “usual suspects”. Read Post